1. Home
  2. MXE vs BOLD Comparison

MXE vs BOLD Comparison

Compare MXE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mexico Equity and Income Fund Inc. (The)

MXE

Mexico Equity and Income Fund Inc. (The)

SELL

Current Price

$12.38

Market Cap

59.7M

Sector

Finance

ML Signal

SELL

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

SELL

Current Price

$2.34

Market Cap

60.8M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
MXE
BOLD
Founded
1990
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
59.7M
60.8M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
MXE
BOLD
Price
$12.38
$2.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.3K
★ 177.2K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 2.66%
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.11
$0.96
52 Week High
$14.30
$3.16

Technical Indicators

Market Signals
Indicator
MXE
BOLD
Relative Strength Index (RSI) 53.64 28.81
Support Level $12.79 $1.40
Resistance Level $13.63 $2.71
Average True Range (ATR) 0.31 0.16
MACD 0.05 -0.03
Stochastic Oscillator 84.11 13.95

Price Performance

Historical Comparison
MXE
BOLD

About MXE Mexico Equity and Income Fund Inc. (The)

Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: